OQROSign up free
Insider trade

Vertex Pharmaceuticals (VRTX): CEO sold ~$7.83M

Reshma Kewalramani, CEO at Vertex Pharmaceuticals, sold ~$7.83M of Vertex Pharmaceuticals shares.

~$7.83M
Approx. value · 15K sh @ $515.00
76K
Holds after · shares reported
Traded
Nov 8, 2024
Filed
Nov 12, 2024

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Oct 2, 2024InsiderOfficer sold ~$461K of VRTX shares in the open market
  2. Nov 8, 2024 · this disclosureInsiderCEO sold ~$7.83M of VRTX shares in the open market

What came next

  1. Nov 11, 2024InsiderCFO sold ~$1.55M of VRTX shares in the open market
  2. Nov 15, 2024InsiderOfficer sold ~$7.2K of VRTX shares in the open market
  3. Dec 13, 2024FDAFDA drug approval: Orkambi
  4. Dec 13, 2024FDAFDA drug approval: Orkambi
  5. Dec 20, 2024FDAFDA drug approval: Alyftrek
  6. Dec 20, 2024FDAFDA drug approval: Trikafta (Copackaged)
  7. Dec 20, 2024FDAFDA drug approval: Trikafta (Copackaged)
  8. Jan 30, 2025FDAFDA drug approval: Journavx
  9. Feb 11, 2025Insider · 4 peopleInsiders: 4 sales (~$3.2M)
  10. Feb 18, 2025Insider · 3 peopleInsiders: 3 sales (~$1.2M)
  11. Feb 20, 2025InsiderOfficer sold ~$533K of VRTX shares in the open market
  12. Feb 25, 2025Insider · 4 peopleInsiders: 4 sales (~$1.9M)
  13. Feb 27, 2025Insider · 3 peopleInsiders: 3 sales (~$2.1M)
  14. Mar 3, 2025InsiderOfficer sold ~$1.58M of VRTX shares in the open market
  15. Mar 4, 2025InsiderOfficer sold ~$1.97M of VRTX shares in the open market
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vertex Pharmaceuticals

For Vertex Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRTX page.

Other recent filings by Reshma Kewalramani, CEO & President

The full history of Reshma Kewalramani, CEO & President is on the profile page.

How this filing works

Explore the data

Other disclosures at Vertex Pharmaceuticals

Everything OQRO holds on this company is on its VRTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data